Pharmaceutical

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Psoriatic Arthritis.

Jan 9, 2024 - 18:00
AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval
AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Psoriatic Arthritis.
Read the original article

Tags:

Previous Article

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood o...

Next Article

Successful Phase 3 Trials Propel Innovent’s Mazdutide into China’s Obesity Market

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The first vaccine for the increasingly prevalent chikungunya virus is here

The first vaccine for the increasingly prevalent chikun...

Nov 11, 2023

Targovax announces plans to rebrand as Circio

Targovax announces plans to rebrand as Circio

Apr 20, 2023

J&J seeks label expansion for Tremfya in ulcerative colitis

J&J seeks label expansion for Tremfya in ulcerative col...

Mar 13, 2024